| Literature DB >> 30116746 |
Matthew W McDonald1, Michelle S Dotzert1, Mao Jiang1, Michael R Murray1, Earl G Noble1,2, C W James Melling1.
Abstract
Intensive insulin therapy (IIT; 4-7 mmol/L) is the preferred treatment for type 1 diabetes mellitus (T1DM) patients to reduce the risk of cardiovascular disease (CVD). However, this treatment strategy has been questioned as it is accompanied with a sedentary lifestyle leading to weight gain and insulin resistance. T1DM patients who partake in high-intensity aerobic training (AThigh) to reduce CVD often utilize conventional insulin therapy (CIT; 9-15 mmol/L) to offset the risk of hypoglycemia. Moreover, exercise modalities incorporating resistance training (RT) have been shown to further reduce this risk. The purpose of this investigation was twofold: (1) to determine if CIT paired with AThigh results in larger cardioprotection from an ischemia-reperfusion (I-R) injury than IIT and (2) to establish if the integration of RT with AThigh (ART) results in similar cardioprotection as AThigh. Diabetic (D) male Sprague-Dawley rats were divided into D-IIT (n = 12), D-CIT (n = 12), D-AThigh (n = 8), D-RT (n = 8), and D-ART (n = 8). T1DM was induced with streptozotocin, and blood glucose was adjusted with insulin. D-AThigh occurred on a treadmill (27 m/min; 1 hr), D-RT performed weighted ladder climbs, and D-ART alternated daily between AThigh and RT. Exercise occurred 5 days/wk for 12 wks. This investigation demonstrates that cardioprotection following an I-R injury was similar between D-AThigh and D-IIT. This cardioprotection is not exercise-specific, and each provides unique advantages. D-AThigh leads to improved glycemia while insulin sensitivity was enhanced following resistance exercises. Thus, exercise is an effective means to elicit cardioprotection in T1DM. However, in addition to glycemia, other factors should be considered when tailoring an exercise program for T1DM patients.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30116746 PMCID: PMC6079594 DOI: 10.1155/2018/8485624
Source DB: PubMed Journal: J Diabetes Res Impact factor: 4.011
General animal characteristics at the completion of the study.
| D-CIT | D-IIT | D-AThigh | D-RT | D-ART | |
|---|---|---|---|---|---|
| Body mass (g) | 567 ± 20 | 598 ± 213,4,5 | 510 ± 15 | 520 ± 21 | 534 ± 19 |
| Blood glucose conc. (mmol/L) | 15.0 ± 1.2 | 10.9 ± 1.21,3,5 | 15.6 ± 0.5 | 12.4 ± 1.95 | 16.7 ± 1.4 |
| Fructosamine conc. (mmol/L) | 3.0 ± 0.5 | 1.0 ± 0.21,5 | 1.3 ± 0.31,5 | 2.0 ± 0.1 | 2.6 ± 0.7 |
| Exogenous insulin (IU) | 27.3 ± 5.4 | 35.8 ± 7.8 | 19.0 ± 7.7 | 11.1 ± 7.12 | 4.1 ± 2.01,2 |
| Insulin resistance (AU) | 10,665 ± 20785 | 16,055 ± 45583,4,5 | 4722 ± 1988 | 1438 ± 623 | 1260 ± 6013 |
Data are means ± SE. 1Different from D-CIT; 2different from D-IIT; 3different from D-AThigh; 4different from D-RT; 5different from D-ART.
Figure 1Left ventricle mechanical performance during ischemia-reperfusion. The data are presented in time course format. LVDP (a), LVEDP (b), +dP/dt (c), −dP/dt (d). ∗Significant main effect (p < 0.05); (φ) different from D-CIT (p < 0.05). Data are presented as a mean ± SE.
Figure 2Left ventricle mechanical performance during ischemia-reperfusion and following different modalities of exercise training. The data are presented in time course format. LVDP (a), LVEDP (b), +dP/dt (c), −dP/dt (d). ψ: different from D‐AThigh (p < 0.05); α: different from D-RT (p < 0.05); β: different from D-ART (p < 0.05). Data are presented as a mean ± SE.
Correlation of left ventricle mechanical performance on glycemia and insulin resistance.
| Versus fructosamine (mmol/L) | Versus insulin resistance (AU) | |||
|---|---|---|---|---|
|
|
|
|
| |
| LVDP (AUC) |
| −0.4 | 0.7 | — |
| LVEDP (AUC) | 0.8 | — | 0.7 | — |
| +dp/dt (AUC) | 0.7 | — |
| −0.4 |
| −dp/dt (AUC) | 0.8 | — | 0.5 | — |
∗Significant (p < 0.05).
Figure 3Left ventricle Hsp70 (a) and SERCA2 (b) protein content. ϕ: different from D-CIT; #: different from D-IIT; α: different from D-RT. Significance p < 0.05. Data are presented as a mean ± SE.
Figure 4Hepatic glycogen content (a), glycogen-6-phosphatase (b), glycogen synthase (MGS: muscle glycogen synthase; LGS: liver glycogen synthase) (c), and glycogen phosphorylase (d). ϕ: different from D-CIT (p < 0.05); #: different from D-IIT (p < 0.05). Data are presented as a mean ± SE.
Blood glucose concentrations in response to exercise at week 11 or week 12 of training.
| Day 1 | Day 2 | |||
|---|---|---|---|---|
| Preexercise (mmol/L) | Postexercise (mmol/L) | Preexercise (mmol/L) | Postexercise (mmol/L) | |
| D-AThigh | 15.0 ± 0.4 | 8.0 ± 1.1∗ | 14.6 ± 0.5 | 6.9 ± 1.0∗ |
| D-RT | 12.2 ± 1.6 | 12.0 ± 0.9 | 13.6 ± 2.2 | 15.1 ± 1.6 |
| D-ART (week 11; RT then AThigh) | 14.9 ± 1.6 | 15.6 ± 1.2 | 15.4 ± 1.7 | 8.0 ± 1.8∗ |
| D-ART (week 12; AThigh then RT) | 16.7 ± 1.4 | 8.8 ± 1.4∗ | 15.2 ± 2.0 | 15.6 ± 1.2 |
Data are means ± SE. ∗Significantly lower than preexercise (p < 0.05).
Epinephrine concentrations in response to exercise at week 11 or week 12 of training.
| Day 1 | Day 2 | |||
|---|---|---|---|---|
| Preexercise (pg/mL) | Postexercise (pg/mL) | Preexercise (pg/mL) | Postexercise (pg/mL) | |
| D‐AThigh | 254.3 ± 44.6 | 93.1 ± 24.9 | 237.0 ± 43.8 | 298.0 ± 109.1 |
| D-RT | 320.8 ± 72.2 | 238.3 ± 58.2 | 110.0 ± 46.1∗ | 136.3 ± 66.3∗ |
| D-ART (week 11; RT then AThigh) | 254.3 ± 107.2 | 150.8 ± 98.0 | 38.7 ± 9.3∗ | 57.8 ± 15.1∗ |
| D-ART (week 12; AThigh then RT) | 331.0 ± 169.8 | 112.6 ± 45.7 | 202.2 ± 33.0 | 184.6 ± 41.8 |
Data are means ± SE. ∗Significantly lower than day 1 (p < 0.05).